Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $41.00 Average Price Target from Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received an average recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $41.00.

Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, December 22nd. Mizuho set a $40.00 target price on Assembly Biosciences and gave the stock an “outperform” rating in a research report on Thursday, November 20th. Citigroup started coverage on Assembly Biosciences in a research note on Wednesday, September 24th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Finally, Guggenheim boosted their price objective on shares of Assembly Biosciences from $31.00 to $39.00 and gave the stock a “buy” rating in a report on Monday, September 8th.

Assembly Biosciences Price Performance

ASMB stock opened at $33.74 on Friday. Assembly Biosciences has a one year low of $7.75 and a one year high of $39.71. The stock has a market cap of $533.77 million, a PE ratio of -7.04 and a beta of 1.14. The firm has a 50 day simple moving average of $34.27 and a two-hundred day simple moving average of $26.66.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 103.65% and a negative return on equity of 59.01%. The company had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $7.46 million. On average, research analysts expect that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Institutional Trading of Assembly Biosciences

Several institutional investors have recently added to or reduced their stakes in ASMB. Ellsworth Advisors LLC bought a new position in Assembly Biosciences during the 3rd quarter valued at approximately $852,000. American Century Companies Inc. purchased a new position in shares of Assembly Biosciences during the first quarter valued at approximately $113,000. Palumbo Wealth Management LLC raised its holdings in shares of Assembly Biosciences by 3.8% during the second quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after acquiring an additional 681 shares in the last quarter. Millennium Management LLC purchased a new stake in Assembly Biosciences in the third quarter worth $553,000. Finally, Farallon Capital Management LLC purchased a new stake in Assembly Biosciences in the third quarter worth $31,426,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.